SEARCH

SEARCH BY CITATION

References

  • 1
    Jackson S. The patient with overactive bladder: Symptoms and quality of life issues. Urology 1997; 50 (Suppl.): 1822.
  • 2
    Abrams P, Wein AJ. The Overactive Bladder. A Widespread and Treatable Condition. Erik Sparre Medical AB, Stockholm, 1998.
  • 3
    Wein AJ, Roberts RW. Overactive bladder survey. Evaluates the extent of symptoms in family doctor setting. Fam. Urol. 2000; 5: 78.
  • 4
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how do we manage them? A population-based prevalence study. Br. J. Urol. Int. 2001; 87: 7606.
  • 5
    Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. Br. J. Urol. Int. 1999; 83: 58390.
  • 6
    Andersson K-E. The overactive bladder: Pharmacologic basis of drug treatment. Urology 1997; 50 (Suppl.): 7484.DOI: 10.1016/s0090-4295(97)00595-5
  • 7
    Yarker YE, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 24362.
  • 8
    Nilvebrant L. The mechanism of action of tolterodine. Rev. Contemp. Pharmacother. 2000; 11: 1327.
  • 9
    Stahl MMS, Eckström B, Sparf A, Mattiasson A, Andersson K-E. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol. Urodyn. 1995; 14: 64755.
  • 10
    Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin. Drug Invest. 2000; 19: 8391.
  • 11
    Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50 (Suppl.): 906.
  • 12
    Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. 1998; 81: 80110.DOI: 10.1046/j.1464-410X.1998.00717.x
  • 13
    Drutz H, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int. Urogynecol. J. 1999; 10: 2839.DOI: 10.1007/s001920050014
  • 14
    Abrams P, Malone-Lee J, Jacquetin B et al. Twelve-month treatment of overactive bladder: Efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 55160.
  • 15
    Clemett D, Jarvis B. Tolterodine: A review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277304.
  • 16
    Millard R, Tuttle J, Moore K et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J. Urol. 1999; 161: 15515.